$0.21
1.22% yesterday
Nasdaq, Nov 15, 09:18 pm CET
ISIN
US19207A1088
Symbol
COEP
Sector
Industry

Coeptis Therapeutics Stock price

$0.20
-0.00 1.00% 1M
-0.16 43.94% 6M
-0.58 74.61% YTD
-1.04 83.95% 1Y
-9.76 98.00% 3Y
-9.70 97.99% 5Y
-9.70 97.99% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.01 3.16%
ISIN
US19207A1088
Symbol
COEP
Sector
Industry

Key metrics

Market capitalization $8.18m
Enterprise Value $8.97m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.15
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-11.26m
Free Cash Flow (TTM) Free Cash Flow $-6.91m
Cash position $1.14m
EPS (TTM) EPS $-0.32
P/E forward negative
Short interest 0.44%
Show more

Is Coeptis Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Coeptis Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Coeptis Therapeutics:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Coeptis Therapeutics:

Buy
100%

Financial data from Coeptis Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 1.03 1.03
37% 37%
-
-1.03 -1.03
-
-
- Selling and Administrative Expenses 6.20 6.20
86% 86%
-
- Research and Development Expense 3 3
45% 45%
-
-10 -10
-
-
- Depreciation and Amortization 1.03 1.03
-
-
EBIT (Operating Income) EBIT -11 -11
78% 78%
-
Net Profit -12 -12
80% 80%
-

In millions USD.

Don't miss a Thing! We will send you all news about Coeptis Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Coeptis Therapeutics Stock News

Neutral
PRNewsWire
9 days ago
Study results demonstrate the safety and feasibility of adoptive immunotherapy using allogeneic off-the-shelf NK cells in hospitalized patients with COVID at high risk for progression of disease DVX201, the first allogeneic NK cell therapy derived from pooled donor cord blood CD34+ cells, was administered to 9 patients with no dose limiting toxicities, cytokine release syndrome or infusion toxi...
Neutral
PRNewsWire
23 days ago
WEXFORD, Pa. , Oct. 24, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced the expansion of its license agreement with Deverra Therapeutics Inc. ("Deverra"), broadening the potential applications of its allog...
Neutral
PRNewsWire
about one month ago
WEXFORD, Pa. , Oct. 15, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, announced that its Chief Scientific and Medical Officer Colleen Delaney, MD will attend and present at the following upcoming fall conferences.
More Coeptis Therapeutics News

Company Profile

Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company. It develops innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. The firm's products include CD38-GEAR-NK, CD38-Diagnostic and GEAR-NK Product. The company was founded in 2017 and is headquartered in Wexford, PA.

Head office United States
CEO David Mehalick
Employees 7
Founded 2017
Website www.coeptistx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today